Basic Ponstan Information

• INN (International Nonproprietary Name): Mefenamic acid
• Brand Names Available In Canada (English): not specified
• ATC Code: M01AG01
• Forms & Dosages: Capsules 250 mg; Tablets 250 mg and 500 mg; Oral suspension 50 mg/5 ml and 100 mg/5 ml (children) — availability by market varies
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Prescription-only (Rx) in most jurisdictions

Latest Research Highlights

Worried whether ponstan still stacks up against common NSAIDs like ibuprofen and naproxen?

Recent Canadian randomized trials specifically on mefenamic acid are limited, so clinicians in Canada rely mainly on international randomized controlled trials, systematic reviews and observational studies through 2022–2024 for guidance.

Meta-analyses cited in the literature show that mefenamic acid provides symptom relief for primary dysmenorrhea comparable to ibuprofen and naproxen when taken at the onset of menses.

Those analyses also report a higher incidence of gastrointestinal upset with mefenamic acid compared with acetaminophen, consistent with fenamate pharmacology.

Safety monitoring since 2020 has emphasised gastrointestinal and renal risk in older adults and patients with comorbidities, aligning with longstanding pharmacovigilance signals for NSAIDs.

There is sparse Canada-specific pharmacoepidemiology on adverse-event frequency, meaning provincial prescribers often rely on international data and Health Canada advisories when counselling patients.

Patient-centred notes from Canadian forums and support groups commonly mention rapid cramp relief but also concern about stomach upset, with many alternating with acetaminophen for tolerance.

Research gaps that matter locally include post-market surveillance in Canada and safety data focused on Indigenous health and rural populations.

Suggested table placements for clinical pages include a summary of randomized trial effect sizes by indication and a safety-signal frequency table for GI, renal and hypersensitivity events.

Clinical Effectiveness In Canada

Are patients in Canada getting the same benefits from ponstan as elsewhere?

Clinical effectiveness considerations in Canada combine international efficacy data with Health Canada regulation and provincial formulary practice.

Mefenamic acid is an NSAID in the fenamate class (ATC M01AG01) used for acute mild-to-moderate pain and primary dysmenorrhea.

Evidence supports symptomatic benefit similar to other NSAIDs for menstrual pain when treatment starts at the onset of menses.

Typical dosing cited for dysmenorrhea is a 500 mg initial dose followed by 250 mg every 6 hours as needed for a short course.

Practical Canadian issues include checking for an active Drug Identification Number (DIN) on Health Canada’s Drug Product Database before prescribing and verifying provincial formulary coverage.

Formulary coverage varies between Ontario Drug Benefit, BC PharmaCare and RAMQ and may require alternatives or special authorization for reimbursement.

Availability through major chains such as Shoppers Drug Mart, London Drugs, Rexall and Jean Coutu affects access in urban and rural settings and supports bilingual labelling where required.

Clinicians should counsel patients on short-term use and monitor for gastrointestinal and renal symptoms during therapy.

Indications And Expanded Uses

What is ponstan commonly prescribed for, and when is it used off-label?

Approved and common uses include treatment of acute mild-to-moderate pain and primary dysmenorrhea, with the dysmenorrhea regimen usually started at menses onset.

Standard adult dosing for dysmenorrhea is an initial 500 mg followed by 250 mg every 6 hours, typically for 2–3 days per period.

For acute pain, short courses up to one week are the common approach.

Off-label uses reported internationally include short-course management of postoperative dental pain and certain acute musculoskeletal pains, although Health Canada–labelled indications and local monographs should guide practice in Canada.

Approved Indications:

• Primary dysmenorrhea: 500 mg initial, then 250 mg q6h as needed (max short-course use)
• Acute mild-to-moderate pain: similar short-course dosing up to 1 week

Common Off-Label Uses:

• Postoperative dental pain — short course
• Certain acute musculoskeletal pains — select cases only

Duration limits are important: avoid continuous long-term use and do not exceed recommended maximum durations for each indication.

Avoid use in children under 14 due to limited safety data; consult before using in elderly or comorbid patients.

Canadian prescribers often pair medication counselling with culturally safe advice and may recommend non-pharmacologic options for Indigenous and rural patients as a first-line preference.

Composition And Brand Landscape

Which formulations and brands of mefenamic acid might patients encounter?

The active ingredient is mefenamic acid (INN), a fenamate NSAID classified under ATC M01AG01.

Common international brands and generics include Ponstel, Ponstan, Meftal and a variety of generic mefenamic acid products distributed globally.

Typical strengths are 250 mg and 500 mg in capsules or tablets, with oral suspensions available in some Asian markets for paediatric use.

In the United States the Ponstel brand has been discontinued in some regions while generics remain available internationally.

For a Canadian context, branded Ponstel or Ponstan availability is not specified in the supplied data, so pharmacists should check Health Canada and DIN listings for local authorizations.

Pharmacy chain substitution policies at Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu determine whether a patient receives a generic equivalent or a special-order brand.

Prescription status is generally prescription-only in most jurisdictions, so ensure correct prescription handling and bilingual labelling where required.

Contraindications And Special Precautions

Who should not take ponstan, and who needs extra monitoring?

Absolute contraindications include known allergy to mefenamic acid, NSAIDs or salicylates, and a history of NSAID-exacerbated asthma or urticaria.

Other absolute contraindications are active peptic ulcer or gastrointestinal bleeding, severe renal or hepatic impairment, and peri-operative use for CABG-related pain.

Relative contraindications that require close monitoring include elderly patients, those with hypertension or cardiovascular disease, and people with mild-to-moderate renal or hepatic impairment.

Patients on anticoagulant or antiplatelet therapy or with prior GI ulcer disease need careful assessment before starting therapy.

In Canadian remote and Indigenous communities where baseline renal disease prevalence may be higher and on-site labs less accessible, conservative use and clear follow-up instructions are advisable.

Report suspected adverse reactions to Canada Vigilance and consult Health Canada advisories for any updates on safety signals.

Patient counselling points should include allergy screening and stopping the medicine immediately if signs of GI bleeding or severe hypersensitivity occur.

Dosage Guidelines

What dose should patients take, and how long is it safe to continue?

Standard adult dosing commonly used is a 500 mg initial dose followed by 250 mg every 6 hours as needed for pain relief.

Maximum typical duration for acute pain is up to one week and for primary dysmenorrhea two to three days per menstrual period.

Children under 14 are generally not recommended to use mefenamic acid because of limited safety data.

Elderly patients should use reduced doses where possible because of increased gastrointestinal and cardiovascular risks associated with NSAIDs.

Renal impairment is a contraindication in severe cases, and mild-to-moderate impairment requires cautious use and monitoring.

Hepatic impairment also warrants monitoring and avoidance in severe dysfunction.

Practical counselling tips include taking the medicine with food to reduce stomach upset and providing bilingual dosing instructions when needed.

If a dose is missed, advise the patient to take it as soon as they remember unless it is close to the next scheduled dose and to never double up.

Interactions Overview

Which medicines and substances commonly interact with ponstan?

Mefenamic acid shares the interaction profile of other NSAIDs and can increase bleeding risk with anticoagulants and antiplatelet agents.

Concurrent use with other NSAIDs or high-dose aspirin increases the risk of gastrointestinal and renal harm and should be avoided.

ACE inhibitors, ARBs and diuretics can have reduced antihypertensive effect and an increased risk of renal impairment when taken with NSAIDs.

Drugs such as lithium and methotrexate may have increased serum levels when co-prescribed with mefenamic acid.

Alcohol consumption raises the risk of GI bleeding, so patients should limit alcohol while on therapy.

Flag the top interactions for patients: anticoagulants/antiplatelets, other NSAIDs, ACE inhibitors/ARBs/diuretics, lithium, methotrexate.

Define interaction severity for patients in simple terms: major (avoid), moderate (monitor), minor (counseling advised).

Encourage patients to notify the pharmacist about all prescription drugs, over-the-counter medicines and herbal supplements, and consider a MedsCheck medication review at the pharmacy.

Cultural Perceptions And Patient Habits

Do Canadian patients trust ponstan, and how do they actually use it?

Canadian attitudes toward NSAIDs like mefenamic acid are pragmatic but cautious, with many patients valuing quick relief for menstrual cramps while worrying about side effects.

Online Canadian forums and patient groups commonly report rapid symptom relief but also a tendency to alternate NSAIDs with acetaminophen due to GI tolerance concerns.

Because mefenamic acid is prescription-only in most places, some patients perceive it as stronger or riskier than over-the-counter options.

Cultural safety and bilingual labelling are important, especially in Quebec and Indigenous communities where clear, respectful counselling improves adherence.

Rural patients often face supply and access challenges with limited pharmacy hours and longer travel times that can delay treatment start.

Cost and formulary coverage drive decisions where provincial reimbursement varies, and out-of-pocket costs for non-formulary brands can be a barrier.

Pharmacies with strong regional presence such as Jean Coutu in Quebec or Shoppers Drug Mart across provinces influence which brands and counselling services patients receive.

Availability And Pricing Patterns

Where can patients in Canada get ponstan and what will it typically cost?

Availability depends on Health Canada authorisation, DIN listings and pharmacy supply chains, and the RAW_DATA does not specify Canadian brands or manufacturers.

International brands such as Ponstel and Ponstan exist, but Canadian stock is often generic and varies by chain and region.

Major pharmacy chains like Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu commonly dispense generics and may offer online ordering with home delivery services subject to provincial rules.

In our online pharmacy, ponstan is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Generic mefenamic acid is usually more economical than branded options, though exact prices depend on the pharmacy and provincial coverage policies.

Cross-border purchasing may sometimes show lower US pricing for specific brands, but importation rules and prescription validity limit practical use.

Clinicians should always check the DIN and provincial formularies (ODB, BC PharmaCare, RAMQ) for coverage and special authorization steps before prescribing.

Comparable Medicines And Preferences

What are the common alternatives to ponstan in Canada and how do they compare?

Common alternatives include ibuprofen, naproxen, diclofenac and ketoprofen for inflammatory pain, and acetaminophen for milder pain or when NSAIDs are contraindicated.

All NSAIDs generally perform well for dysmenorrhea; choice often depends on patient tolerance, cardiovascular and renal risk, cost and formulary availability.

Acetaminophen offers fewer gastrointestinal risks and may be preferred for patients with GI sensitivity or on anticoagulation where NSAIDs are inadvisable.

Clinicians often trial ibuprofen first due to widespread OTC availability and familiarity among patients.

Non-pharmacologic options such as heat therapy, regular exercise and uterine-directed treatments may be recommended in conjunction with or instead of medication.

When switching medications, check provincial DIN-based substitution lists and document the reason for changes for reimbursement where applicable.

Provide patients with a simple pros-and-cons checklist to help choose the right option based on symptoms, risk factors and cost.

FAQ Section

Is ponstan available in Canada without a prescription?

Generally, mefenamic acid is prescription-only in most jurisdictions, and Canada-specific OTC status is not specified in the supplied data.

Can I take ponstan if I am on blood thinners?

No — combining mefenamic acid with anticoagulants or antiplatelet therapy increases bleeding risk and requires medical advice and monitoring.

Is it safe to use ponstan while breastfeeding?

Safety in breastfeeding should be discussed with a prescriber on a case-by-case basis due to limited data; weigh benefits and risks before use.

What should I do if I miss a dose?

Take the missed dose as soon as you remember unless the next dose is near, and do not double the dose.

Where can I find a DIN or check provincial coverage?

Use Health Canada’s Drug Product Database and provincial formulary portals such as ODB, BC PharmaCare and RAMQ for DIN lookup and coverage rules.

Trusted resources for questions include Health Canada, provincial formularies and Canada Vigilance for reporting adverse events, and speak to your local pharmacist at Shoppers Drug Mart, Rexall, London Drugs or Jean Coutu for interaction checks and bilingual counselling.

Guidelines For Proper Use

How should prescribers and pharmacists handle ponstan safely in practice?

Confirm the indication and baseline renal and hepatic function before prescribing, and assess gastrointestinal and cardiovascular risk factors.

Check current medications for interactions with anticoagulants, ACE inhibitors/ARBs, diuretics, lithium and methotrexate prior to initiating therapy.

Document the DIN on prescriptions when required for provincial coverage checks and keep clear notes for reimbursement requests.

Pharmacists should offer a MedsCheck or medication review and provide bilingual dosing and safety counselling where needed.

For rural or remote patients, verify stock availability, give thorough instructions on adverse signs (GI bleeding, reduced urine output) and arrange follow-up contact.

Short Discharge Counselling Checklist:

• Dose and timing, including maximum duration
• When to stop — signs of GI bleeding or severe rash
• When to seek urgent care — black stools, vomiting blood, difficulty breathing
• Storage: keep at 20–25°C and out of reach of children

Encourage reporting adverse events to Canada Vigilance and checking provincial formularies (ODB, BC PharmaCare, RAMQ) for reimbursement steps.

Delivery Across Canada (English)